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Abstract
Background: Long QT syndrome (LQTS) is an inherited cardiac disorder predisposing to sudden cardiac death
(SCD). We studied factors affecting the clinical course of genetically confirmed patients, in particular those not
receiving β-blocker treatment. In addition, an attempt was made to associate risk of events to specific types of
KCNQ1 and KCNH2 mutations.
Methods: A follow-up study covering a mean of 18.6 ± 6.1 years was conducted in 867 genetically confirmed LQT1
and LQT2 patients and 654 non-carrier relatives aged 18–40 years. Cox regression models were used to evaluate
the contribution of clinical and genetic risk factors to cardiac events.
Results: In mutation carriers, risk factors for cardiac events before initiation of β-blocker included LQT2 genotype
(hazard ratio [HR] = 2.1, p = 0.002), female gender (HR = 3.2, p < 0.001), a cardiac event before the age of 18 years
(HR = 5.9, p < 0.001), and QTc ≥500 ms (vs < 470 ms, HR = 2.7, p = 0.001). LQT1 patients carrying the KCNQ1 D317N
mutation were at higher risk (HR = 3.0–3.9, p < 0.001–0.03) compared to G589D, c.1129-2A > G and other KCNQ1
mutation carriers after adjusting for gender, QTc duration, and cardiac events before age 18. KCNH2 c.453delC,
L552S and R176W mutations associated with lower risk (HR = 0.11–0.23, p < 0.001) than other KCNH2 mutations.
Conclusions: LQT2 (compared to LQT1), female gender, a cardiac event before age 18, and long QT interval
increased the risk of cardiac events in LQTS patients aged 18 to 40 years. The nature of the underlying mutation
may be associated with risk variation in both LQT1 and LQT2. The identification of high-risk and low-risk mutations
may enhance risk stratification.
Keywords: Long QT syndrome, Cardiac arrhythmia, Risk stratification, β-blocker, Implantable cardioverter-
defibrillator
Background
Long QT syndrome (LQTS) is a hereditary cardiac
disorder characterized by impaired repolarization prop-
erties of cardiomyocytes which predispose to ventricular
arrhythmias, syncope and sudden cardiac death (SCD).
[1] A total of 16 genes associate with LQTS, and muta-
tions in KCNQ1 or KCNH2 genes cause the most
common subtypes LQT1 and LQT2, respectively. [2] Ac-
cording to recent ESC guidelines, β-blocker treatment
should be initiated if QTc is prolonged, and it may be
useful even with normal QTc. [3, 4] Implantable
cardioverter-defibrillator (ICD) should be applied in
more severe cases. [5, 6]
Presently, genotype and mutation location can be
applied as a part of risk stratification. [7–11] As the
number of molecularly tested mutation carriers in-
creases, mutation-specific assessment might enable more
individually tailored patient management strategies. [12]
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However, the data available for mutation-specific risk
stratification are still limited. [12–16] Previous studies
assessing the clinical course in genotyped subjects have
included children [7, 8] or patients treated with β-
blockers. [9–11, 17–19] In LQTS, the risk associated
with gender and genotype is age-related, [10, 11, 17, 19]
and β-blocker treatment impacts disparate subgroups of
patients differently. [17–19] In the current study, the
clinical course without β-blocker treatment was explored
in genotyped LQT1 and LQT2 patients aged 18–40 years.
In addition, we studied the association of six different




The study population was drawn from the Finnish
Inherited Arrhythmic Disorder Research Registry estab-
lished in 1991 and comprising over 4000 molecularly
tested subjects. The inclusion criteria were 1) genetically
confirmed KCNQ1 or KCNH2 mutation, or genetically
confirmed non-carrier status of the family-specific LQTS
mutation, 2) and the age of more than 18 years at
follow-up end. A questionnaire (Additional file 1) was
sent to the study subjects and collected data included
occurrence of syncope, setting in which syncope
occurred, and data regarding β-blocker therapy. Compli-
ance was defined as forgetting or not taking medication
once a month or more often. The decision whether to
initiate β-blocker therapy was made by the treating
physician upon establishment of the diagnosis.
Data of all deaths during the follow-up were obtained
from Statistics Finland by means of social security num-
ber search. ICD and pacemaker implantations, and left
cardiac sympathetic denervations (LCSD) were identified
using the Finnish Hospital Discharge Register (National
Institute for Health and Welfare). Medical records were
acquired for patients who had device therapy, underwent
LCSD, suffered an aborted cardiac arrest (ACA), or died.
Collected ICD data included implantation indications,
complications, revisions, and ICD discharges. Autopsy
documents of patients who died during the follow-up
were evaluated. The study was approved by the Ethical
Review Committee of Helsinki University Hospital, and
a written informed consent was obtained from the study
subjects. The Ministry of Social Affairs and Health con-
sented for the participation of deceased subjects.
The follow-up study started from the age of 18 years
and ended when the subject 1) returned the question-
naire, 2) turned 40 years [to avoid the effect of acquired
cardiac disease] or 3) was deceased, which ever occurred
first. The end point for statistical analyses was cardiac
event comprising LQTS-related syncope, ACA, appro-
priate ICD shock, or SCD. LQTS-related syncope was
defined as a transient loss of consciousness that was
abrupt in onset and offset, and triggered by one of the
following factors: swimming, other sports, loud noise, or
startle, to avoid inclusion of vasovagal events. [9] Resus-
citation events that required external defibrillation were
defined as ACA. A death was regarded as being SCD if
it was abrupt in onset without evident cause if wit-
nessed, or was not explained by any other cause if it
occurred in an unwitnessed setting such as sleep.
Direct DNA sequencing and restriction enzyme assays
were used in identification of KCNQ1 and KCNH2 muta-
tions as previously described. [20, 21] Mutations were cat-
egorized by mutation type as missense or non-missense
(nonsense, frameshift, splice site, insertion or deletion)
mutations, and by their location as described previously.
[10, 11] Patients carrying more than one LQTS mutation
(n = 7) were excluded from the comparison of the clinical
characteristics and the multivariate risk analyses, but were
included in the sections depicting device therapy. The spe-
cific single mutations included in the final study popula-
tion are detailed in Additional file 2: Table S1. LQT1
Finnish founder (FF) mutations KCNQ1 G589D and
KCNQ1 c.1129-2A >G, and LQT2 FF mutations KCNH2
R176W and KCNH2 L552S were combined to form the
FF mutation population for LQT1 and LQT2, respectively.
Non-carrier family members of the familial KCNQ1 and
KCNH2 mutations served as the comparison group. All
study subjects were of Finnish origin.
Statistical analyses
Clinical characteristics were analyzed using chi-square
and Fisher’s exact tests for categorical, and Wilcoxon
rank-sum and Kruskal-Wallis one-way ANOVA tests for
continuous variables. Kaplan-Meier methods were used
to depict the cumulative incidence rate (=cumulative
probability) of first cardiac event after the age of 18 years
by genotype, gender, QTc interval, and mutation. The
QTc cut-offs used were based on previous LQTS studies.
[4, 7, 18] The significance of the differences was tested
by the log-rank test. Multivariate Cox proportional haz-
ards regression models were used to evaluate the inde-
pendent contribution of genetic and clinical risk factors
to first cardiac event after 18 years of age. Survival was
also evaluated by assessing incidence rates of first car-
diac events per person-years. All cumulative incidence
graphs, log-rank tests, and primary Cox regression and
incidence rate analyses were censored at the initiation of
β-blocker medication. Secondary Cox regression and
incidence rate analyses (Medical Treatment paragraph)
were carried out including the follow-up time with time-
dependent β-blocker medication. No violation of the
proportional hazards assumption was detected as tested
by log-log graphs. A separate QTc missing covariate was
used for mutation carriers whose QTc data were
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unavailable (n = 35). No statistically significant interac-
tions were discovered in interaction term analyses. All
Cox regression models were adjusted for gender, QTc
duration, cardiac events before the age of 18, and family
membership using robust sandwich estimators. Statis-
tical analyses were carried out using SPSS version 22. A
2-sided p-value ≤0.05 was interpreted as statistically
significant.
Results
A total of 2723 subjects fulfilled the inclusion criteria.
The final study population (n = 1521) consisted of 14
subjects who died during the follow-up, 1495 subjects
who responded (55%) to the inquiry, and additional 12
subjects with device therapy drawn from the Hospital
Discharge Register. The study population comprised 867
LQTS mutation carriers (617 KCNQ1, 243 KCNH2, and
seven with > 1 KCNQ1 or KCNH2 mutation), and 654
non-carrier relatives.
The final study cohort had 263 families, and 190 (22%)
of the mutation carriers were probands. The total
follow-up time without β-blocker medication in a sub-
group of 1420 subjects was 18.6 ± 6.0 years. There were
285 subjects who had β-blocker medication at some
point of the study, and the mean follow-up time with
medication was 6.2 ± 5.4 years. Nonresponders (n =
2723–1521 = 1202) had a higher proportion of males
than subjects of the final study population (52% vs 36%,
p < 0.001). There was no difference in the proportion of
LQTS subtypes, or mean QTc duration between these
two groups.
Clinical characteristics
The characteristics of the patients with a single mutation
are shown in Table 1 and with more than one mutation
in Additional file 2: Table S2. Characteristics of the
non-carrier relatives are presented in Additional file 2:
Table S3. Altogether seven of the ten deaths in mutation
carriers, and none of the four deaths in non-carrier rela-
tives were arrhythmia-related. Among mutation carriers
seven (1%) suffered a SCD and eight (1%) at least one
ACA. In LQT1 2% and in LQT2 3% of the cardiac
Table 1 Characteristics of the mutation carriers at the age of 18–40 yearsa
All patients LQT1 LQT2
Non-FF FF Non-FF FF
LQT1 LQT2 D317N Other G589D c.1129-2A > G c.453delC Other L552S R176W
N (%) 617 (72) 243 (28) 20 (3) 72 (12) 453 (73) 72 (12) 23 (10) 61 (25) 73 (30) 86 (35)
Female 396 (64) 157 (65) 17 (85) 48 (67) 282 (62) 49 (68) 11 (48)a, b
c 33 (54)a 56 (77)b 57 (66)a, b
Age, y 36.3 ± 6.2 36.1 ± 6.8 36.5 ± 5.5 35.5 ± 7.2 36.3 ± 6.1 37.4 ± 5.7 35.1 ± 8.2 35.2 ± 7.1 37.0 ± 6.0 36.3 ± 6.9
QTc, ms 467 ± 40 465 ± 41 492±51a
c 473 ± 43b 465 ± 40b 466 ± 28b 466 ± 39a, b, c 487 ± 45a, 466 ± 42b 448 ± 29c
Proband 112 (18)1
b 78 (32)2 1 (5) 18 (25) 76 (17) 17 (24) 0a 34 (56)b 22 (30)c 22 (26)c
β-blocker 184 (30) 65 (27) 11 (55)a 30 (42)a, b 126 (28)a, b 17 (24)b 7 (30)a, b 31 (51)a 14 (19)b 13 (15)b
ICD 9 (2)1 11 (5)2 1 (5) 3 (4) 5 (1) 0 0a, b 9 (15)a 2 (3)a, b 0b
Pacemaker 5 (1)1 8 (3)2 0 0 3 (1) 2 (3) 0a, b 6 (10)a 0b 2 (2)a, b
LCSD 1 (0.2) 1 (0.4) 0 1 (1) 0 0 0 1 (2) 0 0
CE 69 (11)1 43 (18)2 8 (40)a 10 (14)a, b 44 (10)b 7 (10)b 1 (4)a 25 (41)b 9 (12)a 7 (8)a
Syncoped 62 (10)1 39 (16)2 7 (35)a 8 (11)a, b 40 (9)b 7 (10)b 1 (4)a 22 (36)b 9 (12)a 7 (8)a
ACAe 4 (1) 4 (2) 0 1 (1) 3 (1) 0 0 3 (5) 1 (1) 0
SCDf 4 (1) 3 (1) 0 1 (1) 3 (1) 0 0 3 (5) 0 0
CE without BB 55 (10)a 36 (16)b 5 (25)a 7 (10)a, b 36 (8)b 7 (10)a, b 1 (4)a 20 (33)b 8 (11)a 7 (8)a
CE with BB 16 (9) 9 (14) 3 (27) 3 (10) 10 (8) 0 0 7 (22) 2 (14) 0
CE age, yg 26.1 ± 5.91 24.0 ± 5.72 29.5 ± 5.7 25.6 ± 7.0 25.6 ± 5.7 25.5 ± 5.5 18.2 ± 0 23.8 ± 5.5 25.6 ± 7.0 23.6 ± 4.9
CE before age 18 74 (12) 30 (12) 6 (30)a 17 (24)a 46 (10)b 5 (7)b 1 (4) 15 (25) 6 (8) 8 (9)
Parameters shown as n (%), or mean ± SD
aPatients with > 1 LQTS-causing mutation (n = 7) are excluded
bSubscript numbers (1 or 2) indicate that the LQT1 and LQT2 patients have statistically significant difference (p < 0.05)
cSubscript letters (a, b, c or d) indicate that at least one group differs from the other three groups as tested separately within LQT1 and LQT2 patient groups.
Groups with different subscript letters (a, b, c or d) have statistically significant difference after Bonferroni correction (p < 0.05)
dTriggered by swimming, sport, loud noise or startle
eA resuscitation that required external defibrillation
fNot explained by any other cause and abrupt in onset if witnessed
gThe first cardiac event at the age of 18–40 years
ACA: aborted cardiac arrest, BB: β-blocker, CE: cardiac event, FF: Finnish founder, ICD: implantable cardioverter-defibrillator, LCSD: left cardiac sympathetic denerv-
ation, SCD: sudden cardiac death, SD: standard deviation
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events were fatal. Female mutation carriers were more
often probands (26% vs 15%, p = 0.001), and had a longer
QTc (473 vs 454 ms, p < 0.001) as compared with males.
Altogether, QTc duration ≥500 ms was measured in 132
(15%) mutation carriers. One family had 7, three families
had 3, and the remaining families had 0–2 cardiac
events.
Risk factors for cardiac events before β-blocker treatment
LQT2 genotype was associated with a higher risk of car-
diac events in comparison to LQT1 (cumulative prob-
ability 18% vs 11%, p = 0.01; HR = 2.1, p = 0.002, Table 2).
Both LQT1 and LQT2 females were more often
symptomatic than males (cumulative rate 16% vs 3%, p
< 0.001, for LQT1; and 23% vs 8%, p = 0.01, for LQT2,
Figure 1), with a hazard ratio of 3.2 for the female versus
male comparison (p < 0.001). The risk was distinctly
higher in patients who were symptomatic before the age
of 18 years (cumulative rate 52% vs 9%, p < 0.001; HR =
5.93, p < 0.001). QTc duration ≥500 ms increased the
risk 2.7-fold compared to QTc < 470 ms (p = 0.001). We
repeated the analyses after excluding FF mutation car-
riers, and the results regarding genotype, gender, symp-
toms before age 18, and QTc duration were similar.
The risk of cardiac events was higher in mutation car-
riers than in non-carrier relatives even after adjustment
for QTc, gender, and cardiac events before age 18 (Table 3).
In comparison with non-carrier relatives with QTc <
440 ms, mutation carriers with QTc < 440 and ≥ 440 ms
had a 4.2-fold (p = 0.01) and an 11.1-fold (p < 0.001) risk,
respectively, of suffering a cardiac event.
Upon pairwise comparison, KCNQ1 D317N mutation
carriers showed a higher risk of cardiac events than
G589D, c.1129-2G > A or other KCNQ1 mutation
carriers (cumulative probability 40%, 10%, 11% and 14%,
respectively, p = 0.002–0.047, Figure 2; HR = 3.0–3.9, p <
0.001–0.03). Risk or rate of events did not differ between
G589D, c.1129-2G > A and other KCNQ1 mutation car-
riers. Among LQT2 patients the carriers of the c.
453delC, L552S or R176W mutation had fewer cardiac
events than carriers of other KCNH2 mutations (cumu-
lative rate 5%, 13%, 9% and 43%, respectively, p < 0.001–
0.013, Figure 3; HR = 0.11–0.23, p < 0.001).
An analysis of the effect of the mutation site (Table
1S) indicated that the cumulative rate of cardiac events
was higher in patients carrying a missense KCNQ1 non-
FF mutation in pore-loop than in non-pore-loop region
(37% vs 7%, p = 0.01). In a pairwise comparison, pore-
loop mutation carriers also had a higher rate of events
than carriers of a KCNQ1 G589D or c.1129-2G > A
mutation (p = 0.02–0.001), but there was no differ-
ence between non-pore-loop and FF mutation carriers
(p = 0.48–0.53). A similar analysis of the LQT2 patients
showed that among missense KCNH2 non-FF mutation
carriers there was a tendency of higher event rate in pa-
tients with a non-pore-loop than a pore-loop mutation
(58% vs 28%, p = 0.14). Non-pore-loop mutation carriers
had a higher event rate than KCNH2 L552S or R176W
mutation carriers (p < 0.001), and the event rate was
similar between carriers of a pore-loop and a FF mutation
(p = 0.054–0.15).
The rate of cardiac events was the same regardless of
whether the mutation had been inherited from mother
or father as tested separately among all KCNQ1, KCNQ1
G589D, and all KCNH2 mutation carriers (data were
available for 459 KCNQ1 and 150 KCNH2 mutation
carriers).
β-blocker treatment
β-blocker medication was initiated to 249 mutation car-
riers at a mean age of 22.3 and 22.7 years in LQT1 and
LQT2 patients, respectively. Use of medication was more
common in non-FF than FF patients (45% vs 25%, p < 0.
001), and in females than males (34% vs 20%, p < 0.001).
Altogether 27 patients suffered a cardiac event during the
medication, including SCD in four patients. Breakthrough
events were more common in non-FF than FF mutation
carriers (16% vs 7%, p = 0.04). In patients to whom β-
blocker was prescribed, the medication was associated
with 60–81% reduction in the risk of first cardiac event at
the age of 18–40 years (p < 0.001, Table 4).
Non-compliance to β-blocker medication associated with a
1.9-fold (p < 0.001) increase in the risk of cardiac events.
However, the incidence rates of cardiac events in non-
compliant patients were 52.0 and 34.0 per 1000 person-years
before and after initiation of the medication, respectively, in-
dicating a protective impact also in these patients.
Concomitant medications
Treatment with psychotropic agents was equally com-
mon in mutation carriers and non-carrier relatives
Table 2 Cox regression model: Adjusted risk of cardiac events
at the age of 18–40 years in LQT1 and LQT2 patients before
initiation of β-blocker medicationa
Hazard ratio 95% confidence
interval
P-value
LQT2 vs LQT1 2.11 1.33–3.34 0.002
Female vs male 3.18 1.71–5.91 < 0.001
CE vs no CE before age 18 5.93 3.72–9.44 < 0.001
QTc ≥500 vs < 470 ms 2.66 1.53–4.64 0.001
QTc ≥500 vs 470–499 ms 2.22 1.23–4.00 0.01
QTc 470–499 vs < 470 ms 1.20 0.71–2.04 0.50
aPatients with > 1 LQTS-causing mutation (n = 7) are excluded
The model was adjusted for family membership using robust
sandwich estimators
A separate QTc missing covariate was used for patients whose QTc data were
unavailable (n = 35)
CE: cardiac event
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(antidepressants: 5% vs 5%, p = 1.00; antipsychotics: 2%
vs 1%, p = 1.00; anxiolytics: 0.4% vs 0.6%, p = 1.00, re-
spectively). However, mutation carriers who had suffered
a cardiac event reported more often taking daily anti-
depressant drug at the end of the follow-up (12% vs 3%,
p = 0.02).
Device therapy and LCSD
Characteristics of the 39 patients with ICD, pacemaker
or LCSD are detailed in Additional file 2: Table S4. The
incidence rate of cardiac events showed reduction after
ICD implantation: 152.4 and 56.8 per 1000 person-years
before and after implantation, respectively. Similarly,
cardiac events decreased after pacemaker implantation:
82.3 and 0 per 1000 person-years. ICD was implanted
more frequently to non-FF than FF mutation carriers
(7% vs 1%, p < 0.001). Common ICD implantation indi-
cations were ACA, or LQTS-related syncope during
β-blocker medication. An appropriate ICD shock ther-
apy occurred in seven (32%) and an inappropriate shock
in three (14%) patients. Six patients suffered a complica-
tion in the ICD or pacemaker system (incidence rate 26.
8 per 1000 person-years).
Triggers and predisposing factors for SCD and ACA
The patients with SCD, ACA, or ICD shock therapy are
presented in Table 5. Common factors predisposing to
SCD were QT-prolonging medication (n = 4; citalopram,
thioridazine or tizanidine), and absence of β-blocker
therapy (n = 3). Only one β-blocker medication -compli-
ant patient without predisposing factors suffered a SCD.
Of the eight patients who suffered ACA, two were using
a QT-prolonging drug (terfenadine or amiodarone), and
none were on β-blocker medication at the time of the
event.
Fig. 1 Cumulative incidence of cardiac events in LQT1 and LQT2 patients by gender before initiation of β-blocker treatment at the age
of 18–40 years
Table 3 Cox regression model: Adjusted risk of cardiac events
at the age of 18–40 years in mutation carriers and non-carrier
relatives before initiation of β-blocker medicationa
Hazard ratio 95% confidence
interval
P-value
Non-carrierb 1 (reference) – –
KCNQ1 G589D 6.06 3.49–10.5 < 0.001
KCNQ1 c.1129-2A > G 6.83 3.19–14.6 < 0.001
KCNQ1, other mutationsc 8.02 3.43–18.8 < 0.001
KCNQ1 D317N 23.7 11.0–51.1 < 0.001
KCNH2 c.453delC 3.86 1.91–7.79 < 0.001
KCNH2 R176W 5.87 2.89–11.9 < 0.001
KCNH2 L552S 7.80 3.86–15.8 < 0.001
KCNH2, other mutationsc 33.3 18.4–60.3 < 0.001
aPatients with > 1 LQTS-causing mutation (n = 7) are excluded
bMean QTc was significantly longer in all eight mutation carrier groups
mentioned in the Table 3 than in non-carrier relatives (QTc 424 ± 26 and 410
± 22 ms in female and male non-carriers, respectively). The cumulative probability
of cardiac events was 2% in non-carrier relatives
cThe KCNQ1 and KCNH2 mutations in the study are listed in Additional file 2:
Table S1
The model was adjusted for gender, QTc duration, cardiac events before age
18, and family membership
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Fig. 2 Cumulative incidence of cardiac events in LQT1 patients by mutation before initiation of β-blocker treatment at the age of 18–40 years
Fig. 3 Cumulative incidence of cardiac events in LQT2 patients by mutation before initiation of β-blocker treatment at the age of 18–40 years
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Discussion
The present study explored the clinical course of LQTS
in 867 adult KCNQ1 and KCNH2 mutation carriers and
evaluated the risk in six specific mutations. To our
knowledge, this is the largest LQTS study of genotyped
subjects examining the clinical course in the absence of
β-blocker medication, and the first to investigate the
clinical course without β-blocker therapy in adult LQTS
population.
Risk factors for cardiac events
Similar to previous studies, female gender, LQT2 geno-
type, cardiac events before the age of 18, and prolonged
QTc duration were found to increase the risk of cardiac
events. [7, 8, 10, 11, 17–19, 22] In the present study,
mutation carriers with a normal QTc duration (<
440 ms) had a 4.2-fold risk compared to non-carrier rel-
atives, whereas in an earlier study the corresponding risk
was 10-fold. [4] A potential reason for the difference is
the end point of ACA or SCD in the previous study, as
opposed to LQTS-related syncope, ACA, ICD shock, or
SCD in our study. An earlier study demonstrated that
cardiac events among genotype-negative family members
are mostly attributed to nonfatal syncopal episodes. [23]
Although mutation carriers with a normal QTc had a
higher risk than non-carrier relatives, normal QTc asso-
ciated with a good prognosis even in patients left
untreated with β-blockers: none of the previously
asymptomatic non-proband mutation carriers suffered a
cardiac event during the prospective follow-up. This is
of note as cascade screening of family members reveals a
growing number of asymptomatic mutation carriers with
a normal or only slightly prolonged QTc.
Association of the mutation type with clinical events
In the current study, missense KCNQ1 mutations
located in the pore-loop region associated with a higher
rate of cardiac events than non-pore-loop mutations,
which was not seen in a previous study. [24] However,
in the present study most of the pore-loop mutation
carriers had the highly malign KCNQ1 D317N mutation.
Previously, KCNQ1 cytoplasmic loop (c-loop) mutations
have been associated with a higher risk. [11] In our
study, only six patients were carriers of a c-loop muta-
tion precluding exact comparison of c-loop and non-c-
loop mutations. In the present study, KCNH2 mutations
situated in the pore-loop region were not associated with
an increased risk as seen in previous studies. [10, 22] On
the other hand, only 15 subjects had a pore-loop muta-
tion in our analysis.
All four founder mutations had a significant QT-
prolonging effect and associated with increased risk of
cardiac events. Similarly to our recent study of pediatric
LQT1 and LQT2 population, the KCNH2 FF mutations
led to a milder phenotype than non-FF KCNH2 muta-
tions. [14] This might be related to the fact that both
KCNH2 FF mutations lead to a functional channel with
increased deactivation rate, [21, 25] whereas many non-
FF KCNH2 mutations have more dramatic effects on
channel function. However, the risk between KCNQ1 FF
and non-FF mutations did not differ from each other
after excluding the KCNQ1 D317N mutation.
The KCNQ1 D317N mutation appeared exceptionally
malign, and previously it has been shown to associate
with diminished chronotropic response and exaggerated
QTc prolongation after exercise. [26] This mutation is
located in the pore-loop region and leads to complete
loss of channel function with a dominant negative effect
on the wild type channel protein. [27] On the other
hand, the phenotype associated with the KCNH2 c.
453delC mutation turned out to be reasonably mild, in
harmony with an earlier study. [28] This N-terminal mu-
tation leads to a premature termination codon, which
likely targets the mutated mRNA to non-sense mediated
mRNA decay without any dominant negative effect.
Medical treatment
Only 29% of the patients in the present study used
β-blocker medication compared to 45–62% in earlier
studies. [10, 11, 19, 22] However, the previous studies
included adolescents, who are more frequently treated
with β-blockers. [29] In accordance with previous stud-
ies, non-compliance to β-blocker therapy increased the
risk of cardiac events. [14, 30] Nevertheless, also non-
compliant patients demonstrated a decrease in the inci-
dence rate of cardiac events after initiating medication,
which suggests a protective role for β-blockers, even
when present in suboptimal therapeutic concentrations.
Table 4 Time-dependent Cox regression model: Adjusted risk
factors for cardiac events at the age of 18–40 years in the 249
LQT1 and LQT2 patients who were treated with β-blocker
medicationa
Hazard ratio 95% confidence
interval
P-value
BB vs no BB in non-FF 0.40 0.29–0.57 < 0.001
BB vs no BB in KCNQ1 G589D 0.19 0.09–0.41 < 0.001
BB vs no BB in other FF 0.30 0.18–0.51 < 0.001
Non-compliance vs compliance 1.87 1.35–2.59 < 0.001
Side effects vs no side effects 1.08 0.80–1.47 0.61
aPatients with > 1 LQTS-causing mutation (n = 7) are excluded
β-blocker treatment was considered in a time-dependent manner
The effect of β-blocker treatment is shown separately for carriers of non-FF,
KCNQ1 G589D, or other FF mutation
The β-blockers used were bisoprolol (43%), propranolol (33%), atenolol (12%),
metoprolol (10%), acebutolol (2%), and betaxolol (1%)
The model was adjusted for gender, QTc duration, cardiac events before age
18, and family membership
A separate QTc missing covariate was used for patients whose QTc data
were unavailable
BB = β-blocker
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However, considerable proportion of the SCD and ACA
cases associated with insufficient β-blocker medication
underlining the importance of uninterrupted use of pre-
scribed β-blockers.
According to recent ESC guidelines, β-blocker treat-
ment should be initiated if QTc is prolonged, and it may
be useful even with normal QTc duration. [3, 4] The re-
sults of the current study indicate that asymptomatic
adult LQT1 and LQT2 males with FF mutation and QTc
duration < 500 ms have a very low risk, and suggest that
the avoidance of risk factors may be a sufficient measure.
Also, β-blocker medication might not be mandatory for
primary prevention in adult KCNH2 c.453delC mutation
carriers and female FF mutation carriers with QTc <
500 ms. For the remaining patients β-blocker treatment
is recommended.
In the current study, the use of antidepressant drugs
at the end of the follow-up was more common in symp-
tomatic patients. Analysis of a possible causal connec-
tion was not feasible due to limited data on the length of
the antidepressant medication. However, it is possible
that these patients were treated with antidepressants
Table 5 SCD, ACA and ICD shock cases
Case Mutation Age at
event





ACA or ICD shockb
SCD
1 KCNQ1 G589D 35.8 No (non-
compliance)
Unwitnessed Yes No No
2 KCNQ1 G589D 35.0 Yes Unwitnessed, citalopram, ethanol Yes No Syncope (no BB)
3 KCNQ1 c.1032G > A 32.0 Yes Physical exertion, citalopram, ethanol Yes No Syncope (no BB)
4 KCNQ1 G589D 31.3 Yes Awakening, thioridazine Yes No Syncope (no BB)
5 KCNH2 Y569H 25.5 No (non-
compliance)
Awakening, tizanidine, amphetamine Yes No No
6 KCNH2 c.842dupG 24.4 Yes Alarm clock Yes No Syncope (no BB)
7 KCNH2 A558E 21.8 No Awakening No No Syncope (no BB)
ACAc
8 KCNH2 c.643delG 38.8 No No trigger No ICD (39.0) No
9 KCNQ1 G589D 34.5 No Terfenadine, ketoconazole No No Syncope (no BB)
10 KCNH2 P451L 31.5 No Excitement No PM (31.6) No
11 KCNQ1 R518Ter 25.5 No Rest No No No
12d KCNH2 L552S 23.6 No Awakening, amiodarone No ICD (23.6) Syncope (no BB)
13 KCNH2 c.1558-1G > C 23.5 No Rest No ICD (23.5) Syncope (no BB)
14 KCNQ1 G589D 21.0 No Sport No ICD (21.0) No
15 KCNQ1 G589D 20.5 No Post partum period, hypokalemia No ICD (20.5) No
ICD shock
16 KCNQ1 D317N 31.1 Yes Excitement Yes ICD (17.2) Syncope (BB)
17 KCNQ1 G589D 28.3 Yes Excitement Yes ICD (26.9) Syncope (no BB)
12d KCNH2 L552S 25.6 Yes NA Yes ICD (23.6) ACA (no BB)
18 KCNH2 W497Ter 24.0 No (non-
compliance)
Mirtazapine Yes ICD (16.0) Syncope (BB)
19 KCNH2 A561V 21.4 Yes Rest Yes ICD (13.1) ACA (BB),e ICD shock
(BB)e




Pneumonia, disturbance of diabetes
treatment
Yes ICD (15.6) Syncope (BB), ICD
shock (BB)e
21 KCNH2 L552S 19.9 Yes Rest Yes ICD (18.9) Syncope (BB)
aThe age of ICD or pacemaker implantation in parenthesis
bSyncope was triggered by swimming, sport, loud noise or startle. “BB” and “no BB” denote patient was and was not, respectively, using β-blocker at the time of
the cardiac event
cA resuscitation that required external defibrillation
dCase 12 suffered both ACA and ICD shock
eACA or ICD shock before the age of 18 years
fHomozygous mutation carrier
CE: cardiac event, dg: diagnosis, NA: not available, PM: pacemaker, other abbreviations as in Table 1
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already at the time of the cardiac event. Furthermore, four
of the seven SCD cases and two of the eight ACA cases
involved treatment with a potentially QT-prolonging drug.
Therefore, the present and a previous study [30]
emphasize avoidance of QT-prolonging drugs in preven-
tion of potentially life-threatening cardiac events.
Device therapy
The incidence rate of cardiac events showed reduction after
ICD or pacemaker implantation. A potential explanation
arises from bradycardia pacing which has been previously
demonstrated to reduce the risk of ICD shocks in high-risk
patients. [5] However, in the current study, the initiation of
β-blocker therapy was coincidental with device implant-
ation in 18 of the 37 cases. Therefore, the reduction in car-
diac events might be attributable to β-blocker treatment.
Study limitations
There are a number of noteworthy limitations in our
study. First, only 55% of the patients initially surveyed
responded to our inquiry leading to a possibility of selec-
tion bias. Second, comparison of patients with different
mutation categories occasionally resulted in relatively
small patient subgroups. Third, initiation of β-blocker
medication was not standardized across participants lead-
ing to a concern about confounding by indication. Fourth,
we have performed rather many statistical comparisons
which may increase the number of false positive findings.
Conclusions
Molecularly defined LQT1 and LQT2 patients who sur-
vive till adulthood continue to be at risk of cardiac
events. The clinical risk factors for cardiac events in pa-
tients without β-blocker medication were mostly found
to be similar to those reported in previous studies that
included patients treated with β-blockers. Specific
KCNQ1 and KCNH2 mutations were associated with
varied risk of cardiac events, independently of gender,
QTc duration, and cardiac events before the age of 18.
The identification of high-risk and low-risk mutations
may enhance risk stratification, and may help to reveal
patient groups in which lifestyle modifications are a suf-
ficient measure.
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